Trial Profile
A Phase 1b Open-Label Study Assessing the Pharmacokinetics, Tolerability, and Safety of Oral Trimetazidine in Subjects With Acute-on-Chronic Liver Failure
Status:
Suspended
Phase of Trial:
Phase I
Latest Information Update: 04 Nov 2021
Price :
$35
*
At a glance
- Drugs Trimetazidine (Primary)
- Indications Liver failure
- Focus Pharmacokinetics
- Acronyms TRUST
- Sponsors Martin Pharmaceuticals
- 02 Mar 2021 Planned End Date changed from 30 Jun 2020 to 30 Jun 2021.
- 02 Mar 2021 Planned primary completion date changed from 28 Feb 2020 to 30 Jun 2021.
- 02 Mar 2021 Status changed from recruiting to suspended due to lack of enrollment.